United States:
Trends In Inter Partes Review Of Life Sciences Patents
To print this article, all you need is to be registered or login on Mondaq.com.
A statistical analysis of inter partes review proceedings before
the Patent Trial and Appeal Board shows that the PTAB is not a
''death squad'' for patents.
Click here to read the full text of this article.
Originally published by Bloomberg BNA
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from United States
Are Your NDAs Up To Date?
Wolf, Greenfield & Sacks, P.C.
Nondisclosure agreements (NDAs) can be used to protect companies' confi dential and trade secret information. But you should resist the urge to have a vendor...
Legal Implications Of New York Times vs. OpenAI
BoyarMiller
The New York Times recently filed a landmark lawsuit against OpenAI and Microsoft, accusing them of copyright infringement in the training of the chatbot ChatGPT which launched just over a year ago.
